Nizar M. Tannir

The University of Texas MD Anderson Cancer Center — United States

Medicine · Health Sciences

83h-index31.1kcitations1.0kworks2.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Renal cell carcinoma treatment(627), Renal and related cancers(350), Cancer Genomics and Diagnostics(250), Cancer Immunotherapy and Biomarkers(174), Bladder and Urothelial Cancer Treatments(106)

Publications1.0k total

Supplementary Data 1 from SETD2 Loss and ATR Inhibition Synergize to Promote cGAS Signaling and Immunotherapy Response in Renal Cell Carcinoma
2025Open Access
Nivolumab plus ipilimumab induce hyper-progression in renal medullary carcinoma: results of a phase II trial and preclinical evidence
Nature Communications·2025· 1 citedOpen Access
Table S1 from Differential Efficacy of Bevacizumab and Erlotinib in Preclinical Models of Renal Medullary Carcinoma and Fumarate Hydratase–Deficient Renal Cell Carcinoma
2025Open Access
Figure S2 from Differential Efficacy of Bevacizumab and Erlotinib in Preclinical Models of Renal Medullary Carcinoma and Fumarate Hydratase–Deficient Renal Cell Carcinoma
2025Open Access
Figure S1 from Differential Efficacy of Bevacizumab and Erlotinib in Preclinical Models of Renal Medullary Carcinoma and Fumarate Hydratase–Deficient Renal Cell Carcinoma
2025Open Access
Table S2 from Differential Efficacy of Bevacizumab and Erlotinib in Preclinical Models of Renal Medullary Carcinoma and Fumarate Hydratase–Deficient Renal Cell Carcinoma
2025Open Access
Data from Differential Efficacy of Bevacizumab and Erlotinib in Preclinical Models of Renal Medullary Carcinoma and Fumarate Hydratase–Deficient Renal Cell Carcinoma
2025Open Access
Figure S4 from Differential Efficacy of Bevacizumab and Erlotinib in Preclinical Models of Renal Medullary Carcinoma and Fumarate Hydratase–Deficient Renal Cell Carcinoma
2025Open Access
Figure S3 from Differential Efficacy of Bevacizumab and Erlotinib in Preclinical Models of Renal Medullary Carcinoma and Fumarate Hydratase–Deficient Renal Cell Carcinoma
2025Open Access
1057 Early targeted biologics are associated with improved clinical outcomes in immune-related myocarditis, myositis, and myasthenia gravis
Regular and Young Investigator Award Abstracts·2025Open Access
1064 Clinical and prognostic characterization of high-grade neurologic immune-related adverse events in patients with urinary cancers
Regular and Young Investigator Award Abstracts·2025Open Access
Identification of therapeutic targets for renal medullary carcinoma via integrated genomic and transcriptomic profiling
Cell Reports Medicine·2025Open Access
Management of Renal Cell Carcinoma of Variant Histology
JCO Oncology Practice·2025· 1 cited
A multicenter randomized phase II trial of lenvatinib plus everolimus versus cabozantinib in patients with metastatic clear-cell RCC that progressed on PD-1 immune checkpoint inhibition (LenCabo)
Annals of Oncology·2025· 2 citedOpen Access
20Phase II trial of ivonescimab in patients with advanced clear cell renal cell carcinoma previously treated with immune checkpoint blockade: IVORY trial (NCT06940518)
The Oncologist·2025Open Access
7Phase 2 trial of metastasis directed radiotherapy without systemic therapy (MRWS) for oligometastatic clear cell renal cell carcinoma (ccRCC) and investigation of circulating tumor DNA (ctDNA)
The Oncologist·2025Open Access
Metastasis-directed radiotherapy without systemic therapy for oligometastatic clear-cell renal-cell carcinoma: primary efficacy analysis of a single-arm, single-centre, phase 2 trial
The Lancet Oncology·2025· 5 cited
2596MO Phase Ib/II trial of ipilimumab, nivolumab, and ciforadenant (adenosine A2a receptor antagonist) in first-line advanced renal cell carcinoma (RCC), a kidney cancer research consortium study
Annals of Oncology·2025Open Access
987P Phase I study of tumor treating fields (TTFs) with cabozantinib or with nab-paclitaxel and pembrolizumab in patients with advanced solid tumors involving the abdomen or thorax
Annals of Oncology·2025
LBA94 LenCabo: A randomized phase II multicenter trial of lenvatinib plus everolimus (len/eve) versus (vs) cabozantinib (cabo) in patients (pts) with metastatic clear cell RCC (ccRCC) that progressed on PD-1 immune checkpoint inhibition (ICI)
Annals of Oncology·2025· 1 citedOpen Access
page 1 of 52Next →

Frequent Co-authors

Eric Jonasch(14), Pheroze Tamboli(13), Robert J. Motzer(12), Toni K. Choueiri(12), Christopher G. Wood(11), Frede Donskov(10), David F. McDermott(10), Thomas Powles(9), Brian I. Rini(9), Bernard Escudier(9), Surena F. Matin(9), Elizabeth R. Plimack(8), Hans J. Hammers(8), Camillo Porta(7), Saby George(7), Howard Gurney(7), Yoshihiko Tomita(7), M. Brent McHenry(7), Christian Kollmannsberger(6), Marc‐Oliver Grimm(6)